Progress of vaccine and drug development for Ebola preparedness
Clinical and Experimental Vaccine Research
; : 11-16, 2015.
Article
em En
| WPRIM
| ID: wpr-119876
Biblioteca responsável:
WPRO
ABSTRACT
Since the first case of Ebola virus disease (EVD) in Guinea was reported in March 2014 by World Health Organization (WHO), the outbreak has continued through the year and the total number of 19,065 patients was reported as the confirmed or suspected in the EVD-affected countries. Among the cases, 7,388 patients were reported death by 19 December. Currently, available therapeutics to treat the infected patients or vaccines to prevent people from infection is not developed yet while viral diagnostic methods were already developed and firmly established in a lot of countries as a first step for the preparedness of Ebola outbreak. Some potential therapeutic materials including ZMapp were supplied and the treated people got over the EVD. Several candidates of vaccines also were investigated their efficacy in animal models by National Institute of Health (NIH) and Department of Defense, and they are processing of clinical tests in West Africa aiming to finish the development by the 2015. Vaccine and therapeutic development is essential to stop the EVD outbreak in West Africa, also to protect the world from the risk which can be generated by potential spread of Ebola virus.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Organização Mundial da Saúde
/
Vacinas
/
Guiné
/
Doença pelo Vírus Ebola
/
Modelos Animais
/
África Ocidental
/
Ebolavirus
Limite:
Humans
País/Região como assunto:
Africa
Idioma:
En
Revista:
Clinical and Experimental Vaccine Research
Ano de publicação:
2015
Tipo de documento:
Article